Ramesh Ratan Biography and Net Worth

CFO of Entera Bio

Seasoned finance executive with extensive experience in the Pharmaceutical and Biotechnology industry. Worked for big pharma, biotech, and high-tech start-ups in both public and private sectors. Responsible for all aspects of CFO functions and manufacturing, including offshore manufacturing of GMP products for clinical trials. Significant cost savings for offshore GMP production. Built a proactive accounting and finance group. Worked very closely with CEO’s and an executive member of the management team providing strategic guidance. Have a problem solving and positive can-do attitude. Recently, did a $160 million Series C round of financing. Filed for a biotech IPO on the Hong Kong exchange. Have done public and private rounds of financing and raised more than $500 million. Worked closely with public and private investors.

How do I contact Ramesh Ratan?: The corporate mailing address for Mr. Ratan and other Entera Bio executives is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. Entera Bio can also be reached via phone at (722) 532-7151 and via email at [email protected]. Learn More on Ramesh Ratan's contact information.
Has Ramesh Ratan been buying or selling shares of Entera Bio?: Ramesh Ratan has not been actively trading shares of Entera Bio during the last quarter. Most recently, on Wednesday, January 19th, Ramesh Ratan bought 10,000 shares of Entera Bio stock. The stock was acquired at an average cost of $2.44 per share, with a total value of $24,400.00. Learn More on Ramesh Ratan's trading history.
Who are Entera Bio's active insiders?: Entera Bio's insider roster includes Yonatan Malca (Director), Ron Mayron (Director), and Ramesh Ratan (CFO). Learn More on Entera Bio's active insiders.
Are insiders buying or selling shares of Entera Bio?: In the last year, Entera Bio insiders bought shares 4 times. They purchased a total of 81,067 shares worth more than $56,274.47. The most recent insider tranaction occured on January, 12th when Director Haya Taitel bought 9,500 shares worth more than $9,405.00. Insiders at Entera Bio own 8.9% of the company. Learn More about insider trades at Entera Bio.
Information on this page was last updated on 1/12/2024.

Ramesh Ratan Insider Trading History at Entera Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/19/2022	Buy	10,000	$2.44	$24,400.00

Ramesh Ratan Buying and Selling Activity at Entera Bio

Entera Bio Company Overview

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Today's Range

Now: $2.00

$1.93

$2.07

50 Day Range

MA: $1.65

$1.03

$2.98

2 Week Range

Now: $2.00

$0.52

$3.35

Volume

117,197 shs

Average Volume

209,199 shs

Market Capitalization

$57.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report